The prophylactic effect of Hydroxychloroquine on Novel Corona virus

INTERVENTION: Intervention 1: Intervention group: They will receive 400 mg of hydroxychloroquine (Tehran Darou, Iran) a week for eight weeks and also this group will receive routine care for Corona's new disease. Intervention 2: Control group: They will receive routine care for Corona's new disease. CONDITION: COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Serum CRP levels and cellular immunity (cd8 / cd4 ratio) are assessed at the beginning and end of the study for all subjects. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist. The number of confirmed cases. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist. The two groups will also be examined in terms of disease severity (need for intubation, ICU hospitalization) and absolute lymphocyte count. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist. INCLUSION CRITERIA: consent to participate in the study People working in medical centers in Arak city Lack of sensitivity to hydroxychloroquine Lack of G6PD Lack of porphyria No breastfeeding No pregnancy Lack of diabetes, kidney , liver and skin disease